Furthermore, phenformin could also display synergism with other anti-cancer molecules (i.e., immune-therapeutics, chemotherapeutic)
Food and Drug Administration recently issued a warning against using unapproved GLP-1 drugs for weight loss, citing quality concerns, false or misleading labels, counterfeit drugs and more than 1,600 reports of adverse effects associated with compounded GLP-1 medications
However, to the best of our knowledge, to date, no data has been reported on whether GLP-1R exerts an anti-inflammatory effect on OA through inhibition of the PKA/CREB pathway
Even though obesity and other metabolic disorders are known to be higher in IBD patients, medications to treat obesity in this population are underutilized